vimarsana.com
Home
Live Updates
FDA Clears Cingulate to File for Marketing Approval of CTx-1
FDA Clears Cingulate to File for Marketing Approval of CTx-1
FDA Clears Cingulate to File for Marketing Approval of CTx-1301 in the Treatment of ADHD
Phase 3 Data Collected to Date Sufficient for Submission of New Drug Application CTx-1301 Could Benefit >60% of ADHD Patients Currently ...
Related Keywords
United States ,
Kansas City ,
Kansas ,
American ,
Shanej Schaffer ,
Matt Kreps ,
Thomas Dalton ,
Ann Childress ,
Drug Administration ,
Behavior Medicine Inc ,
Platform Technology ,
Securities Exchange ,
Darrow Associates ,
Psych Congress First Annual Poster ,
Exchange Commission ,
Psych Congress ,
Nasdaq ,
Cingulate Inc ,
American Professional Society ,
Date Sufficient ,
New Drug Application ,
Currently Using Immediate Release Booster ,
Precision Timed Release ,
Attention Deficit Hyperactivity Disorder ,
Cingulate Chairman ,
Behavior Medicine ,
Professional Society ,
Related Disorders ,
First Annual Poster ,
Hyperactivity Disorder ,
Erosion Barrier Layer ,
Looking Statements ,
Securities Act ,
Securities Exchange Act ,
Annual Report ,
Public Relations ,